pevonedistat
Pevonedistat, also known as MLN4924, is an investigational small-molecule inhibitor of the NEDD8-activating enzyme (NAE). By inhibiting NAE, it blocks the neddylation of cullin-RING ligases (CRLs), leading to stabilization of CRL substrates, replication stress, cell-cycle arrest, and apoptosis in cancer cells.
Pevonedistat has been evaluated in phase I and II clinical trials, alone and in combination with other
In trials, pevonedistat is generally administered by intravenous infusion on cycles that vary by study; the
Ongoing research seeks to define optimal combinations, dosing strategies, and patient populations that may benefit from